TNDM - Tandem Diabetes Care, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
26.93
+1.04 (+4.02%)
At close: 4:00PM EDT

26.80 -0.13 (-0.48%)
After hours: 4:35PM EDT

Stock chart is not supported by your current browser
Previous Close25.89
Open25.98
Bid26.50 x 800
Ask26.87 x 2900
Day's Range25.45 - 27.25
52 Week Range2.14 - 27.25
Volume3,300,626
Avg. Volume2,636,812
Market Cap1.348B
Beta-0.69
PE Ratio (TTM)N/A
EPS (TTM)-8.74
Earnings DateJul 25, 2018 - Jul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.36
Trade prices are not sourced from all markets
  • Business Wire32 minutes ago

    Tandem Diabetes Care Schedules Second Quarter 2018 Earnings Press Release and Conference Call

    Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its second quarter 2018 results after the financial markets close on Monday, July 30, 2018.

  • ACCESSWIRE4 days ago

    Free Stock Performance Review on TransEnterix and Three Additional Medical Supplies Stocks

    LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. WallStEquities.com takes a close look at four Medical Instruments and Supplies stocks, particularly, Tandem Diabetes Care Inc. (NASDAQ: TNDM), The Cooper Cos. Inc. (NYSE: COO), TransEnterix Inc. (NYSE American: TRXC), and Waters Corp. (NYSE: WAT).

  • 2 Stocks That Turned $1,000 Into More Than $8,000 This Year
    Motley Fool7 days ago

    2 Stocks That Turned $1,000 Into More Than $8,000 This Year

    Just because risky stocks become winners doesn't mean you should be casting your lot with them.

  • The 5 Best Healthcare Stocks of 2018 (So Far)
    Motley Fool7 days ago

    The 5 Best Healthcare Stocks of 2018 (So Far)

    Here's what's pushing up the top-performing, non-pharmaceutical healthcare stocks.

  • 3 Best Diabetes Stocks of 2018 So Far
    Motley Fool13 days ago

    3 Best Diabetes Stocks of 2018 So Far

    These diabetes stocks gained at least 50% in the first half of the year. But can the momentum continue?

  • Tandem Diabetes Care’s Stock Performance This Month
    Market Realist18 days ago

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump. On June 26, Tandem stock was trading ~1,000% higher than the 52-week low of $2.14 it reached on February 9.

  • What Tandem Diabetes Care Expects for This Year
    Market Realist18 days ago

    What Tandem Diabetes Care Expects for This Year

    In fiscal 2018, Tandem Diabetes Care (TNDM) expects sales at the mid-to-upper end of its $132 million–$140 million guidance. This confident sales outlook comes despite the company discontinuing its t:flex insulin pump by the end of fiscal Q2 2018. The company registered sales of $102.6 million in fiscal 2017 and $27.3 million in Q1 2018, ahead of analysts’ estimates.

  • Tandem Diabetes Care’s International Expansion Strategy
    Market Realist18 days ago

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care Rises 21%: Could It See More Upside? Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017. At the time, the move largely benefited Medtronic (MDT), the largest player in the insulin pump market.

  • Analysts’ Views on Tandem Diabetes Care after Its FDA Approval
    Market Realist18 days ago

    Analysts’ Views on Tandem Diabetes Care after Its FDA Approval

    After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump. Following the news, Oppenheimer analyst Steven Lichtman shared his views on Tandem, writing, “Approval timing is in line, though compatibility with Dexcom’s new G6 sensor in the initial approval is upside to expectations; TNDM had assumed a staggered approval with G5 compatibility first, potentially followed shortly thereafter by iCGM designation/G6 compatibility.” He added, “Earlier G6 approval bodes well for the initial launch later this summer. ...

  • Tandem’s Product Shipments Continue to Rise
    Market Realist19 days ago

    Tandem’s Product Shipments Continue to Rise

    Apart from selling insulin pumps, Tandem Diabetes Care (TNDM) also sells disposable products that are used together with pumps and are replaced every few days. These include cartridges and infusion sets. Tandem’s products on the market include t:slim, t:flex, and t:slim G4. In October 2016, Tandem commercialized t:slim X2 and discontinued t:slim. At present, the t:slim X2 platform represents almost the entire new pump shipments of the company. Tandem plans to discontinue sales of t:flex pumps from Q3 2018.

  • What to Expect from Tandem’s Product Pipeline
    Market Realist19 days ago

    What to Expect from Tandem’s Product Pipeline

    Tandem Diabetes Care’s (TNDM) t:slim X2 with control IQ is its second generation AID system that is expected to integrate the t:slim X2 pump with the technology Tandem licensed from TypeZero Technologies and Dexcom’s (DXCM) G6 sensor. In its international diabetes closed loop (or IDCL) trial, Tandem is working with TypeZero and Dexcom on the integration of their technologies. Further, Tandem plans to use these results in a premarket approval (or PMA) submission to the U.S. Food and Drug Administration (or FDA).

  • Analyzing Tandem’s Operational Performance
    Market Realist19 days ago

    Analyzing Tandem’s Operational Performance

    Due to the decrease in SG&A expenses, the total operating expenses of Tandem Diabetes Care decreased from $28.0 million in Q1 2017 to $26.9 million in Q1 2018, which further helped the company in reducing its operating loss to $15.5 million in Q1 2018 as compared with an operating loss of $21.2 million in Q1 2017.

  • A 58% Jump in Pump Shipments Bodes Well for Tandem
    Market Realist19 days ago

    A 58% Jump in Pump Shipments Bodes Well for Tandem

    The company earns revenues from the sale of insulin pumps, infusion sets, and cartridges. In comparison, in Q1 2017, infusion set sales generated $3.4 million and cartridge sales generated $2.9 million.

  • How Tandem’s Cash Flows and Valuations Are Trending
    Market Realist19 days ago

    How Tandem’s Cash Flows and Valuations Are Trending

    In Q1 2018, Tandem Diabetes Care (TNDM) used $12.3 million in operating activities as compared with $20.8 million in Q1 2017. This decrease was attributable to a decline in the net loss after adjusting for non-cash expenses and net changes in working capital.

  • What Do Analysts Think of Tandem Diabetes Care?
    Market Realist19 days ago

    What Do Analysts Think of Tandem Diabetes Care?

    Tandem Diabetes Care (TNDM) is a medical devices manufacturer. Its products are targeted at people with insulin-dependent diabetes. Five of the total six analysts covering Tandem Diabetes Care in June have given the stock a “buy” or a higher rating, while one analyst has given it a “hold” rating.

  • Tandem Diabetes Care Inc (NASDAQ:TNDM): Time For A Financial Health Check
    Simply Wall St.19 days ago

    Tandem Diabetes Care Inc (NASDAQ:TNDM): Time For A Financial Health Check

    While small-cap stocks, such as Tandem Diabetes Care Inc (NASDAQ:TNDM) with its market cap of US$1.18b, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • InvestorPlace21 days ago

    Why Tandem Stock Could Continue Its Rally

    If you’ve been with Tandem Diabetes Care (NASDAQ:TNDM) since in the early innings of its massive rally in April, you really enjoyed the over 13 percent rally on Friday. The main cause was the FDA approval of Tandem’s t:slim X2 Insulin Pump with Basal-IQ. On June 21, the FDA approved Senseonics Holdings’ (NYSEAMERICAN:SENS) Eversense Continuous Glucose Monitoring (“CGM”) System.

  • Company News For Jun 25, 2018
    Zacks21 days ago

    Company News For Jun 25, 2018

    Companies In The News are: RHT,BB,KMX,TNDM

  • Tandem Diabetes Takes Aim at Medtronic's Artificial Pancreas
    Motley Fool22 days ago

    Tandem Diabetes Takes Aim at Medtronic's Artificial Pancreas

    The FDA signed off on the upstart's automatic insulin delivery system.

  • Benzinga24 days ago

    Oppenheimer: After FDA Approval Of Tandem's Insulin Pump, Investor Focus Will Shift To 2018 Opportunities

    Late Thursday, Tandem Diabetes Care Inc (NASDAQ: TNDM ) announced FDA approval of its t:slim X2 insulin pump with Basal-IQ for Type 1 diabetes patients, which is planned for an August launch. With the ...

  • Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump
    Market Realist24 days ago

    Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump

    Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology yesterday after the market closed. Today, Medtronic (MDT) and Insulet (PODD), other major players in the insulin pump market, opened ~0.42% and ~0.74% higher, respectively, than yesterday’s closing prices. Tandem Diabetes Care’s recently approved t:slim X2 insulin pump features Basal IQ technology, which helps reduce the frequency and duration of the events characterized by low glucose levels with a “predictive low glucose suspend” feature.

  • Big News Sends Tandem Diabetes Soaring 10.2% Today
    Motley Fool24 days ago

    Big News Sends Tandem Diabetes Soaring 10.2% Today

    The FDA has given the OK to the company's automated insulin system.

  • Benzinga24 days ago

    Tandem Diabetes Rallies After FDA Approves Insulin Pump With New Technology

    The medical device maker announced Thursday the FDA approved its t:slim X2 Insulin pump with Basal-IQ technology. Tandem Diabetes expects to make the t:slim X2 pump with Basal-IQ technology available in the U.S. in August.

  • CNBC25 days ago

    After-hours buzz: RHT, CMC & more

    Check out the companies making headlines after the bell: Shares of Red Hat RHT plummeted more than 11 percent in extended-hours trading, after the company reported better than expected first quarter earnings and revenue , but reported weak guidance.

  • Business Wire25 days ago

    Tandem Diabetes Care Announces FDA Approval of t:slim X2 Insulin Pump with Basal-IQ Technology

    Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.S. Food and Drug Administration (FDA) approval of the t:slim X2™ Insulin Pump with Basal-IQ™ technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia). This is the first automated insulin delivery system approved for use by children as young as 6 years old, and the first insulin pump designated as compatible with integrated continuous glucose monitoring (iCGM) devices.